Skip to content
Copanlisib
Aliqopa (copanlisib) is a small molecule pharmaceutical. Copanlisib was first approved as Aliqopa on 2017-09-14. It is used to treat follicular lymphoma in the USA. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Aliqopa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Copanlisib dihydrochloride
Tradename
Company
Number
Date
Products
ALIQOPABayerN-209936 RX2017-09-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
aliqopaNew Drug Application2020-11-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
follicular lymphoma—D008224C82
Agency Specific
FDA
EMA
Expiration
Code
COPANLISIB DIHYDROCHLORIDE, ALIQOPA, BAYER HEALTHCARE
2024-09-14ODE-155
Patent Expiration
Patent
Expires
Flag
FDA Information
Copanlisib Dihydrochloride, Aliqopa, Bayer Healthcare
96363442032-03-29U-2124
103838762032-03-29DS, DP
RE468562029-10-22DS, DPU-2124
75110412024-05-13DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EM: Phosphatidylinositol-3-kinase (pi3k) inhibitors
— L01EM02: Copanlisib
HCPCS
Code
Description
J9057
Injection, copanlisib, 1 mg
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyponatremiaD007010HP_0002902E87.12—72—11
Heart failureD006333EFO_0003144I50—11215
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.911———2
Brain edemaD001929EFO_1000845G93.611———2
Liver cirrhosisD008103EFO_0001422K74.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K772————2
Cerebral hemorrhageD0025431————1
Traumatic brain injuriesD000070642S061————1
Kidney diseasesD007674EFO_0003086N081————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary hypertensionD006976EFO_0001361I27.20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCOPANLISIB
INNcopanlisib
Description
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
Classification
Small molecule
Drug classphosphatidylinositol 3-kinase (PI3K) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21
Identifiers
PDB—
CAS-ID1032568-63-0
RxCUI—
ChEMBL IDCHEMBL3218576
ChEBI ID—
PubChem CID24989044
DrugBankDB12483
UNII IDWI6V529FZ9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PIK3CD
PIK3CD
PIK3CG
PIK3CG
PIK3CB
PIK3CB
MTOR
MTOR
PIK3CA
PIK3CA
Organism
Homo sapiens
Gene name
PIK3CD
Gene synonyms
NCBI Gene ID
5293
Protein name
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Protein synonyms
p110delta, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 8/20, phosphoinositide-3-kinase C, phosphoinositide-3-kinase, catalytic, delta polypeptide variant p37delta, PI3-kinase p110 subunit delta, PI3Kdelta, PtdIns-3-kinase subunit p110-delta
Uniprot ID
Q5SR49
Mouse ortholog
Pik3cd (18707)
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Q8CJ28)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,118 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
62 adverse events reported
View more details